×

Kaneh Bosm BioTechnolgy Inc.: BioCanna ADM to Commence Field Testing in Vancouver, British Columbia in Mid-April

VANCOUVER, British Columbia, April 9, 2015 (GLOBE NEWSWIRE) -- Kaneh Bosm BioTechnolgy Inc. (KBB:CSE) ("Kaneh Bosm" or the "Company") is very pleased to announce that the Company's automated Cannabis retail system, the BioCanna ADM will arrive in Vancouver, British Columbia in mid-April. Initially 2 units will be arriving from Europe to partake in this preliminary trial. The units will be tested to ensure full functionality for Cannabis dispensing.

The BioCanna ADM is a hybrid between a bank ATM, and an intelligent retail kiosk. This system provides proven software for point of sale transaction and inventory management, secure climate controlled product storage, a reduction in labor costs, age-verification or patient eligibility requirements, and potential 24/7 availability.

The superior BioCanna ADM retail system is European based, designed and manufactured by Majex Italy. Presently, there are more than 2000 Majex Italy units operating across Western Europe many in the retail pharmaceutical dispensing marketplace. The kiosks are proven to be reliable and profitable.

The BioCanna ADM retail system is unique in this sector as it encompasses 5 crucial elements to safe, reliable, and successful automated Cannabis retail. Those elements are:

(i) access control (no minors or un-prescribed patients),
(ii) purchase volume control (monthly or daily quantity limits),
(iii) secure storage of product (climate controlled and theft proof),
(iv) transactional oversight by regulators via software monitoring, and
(v) a track record in a controlled substance/products environment.

The BioCanna ADM system is available for deployment to Cannabis retailers with a number of flexible programs with varying rental rates, and transaction fees. The units will also available for purchase for a limited time.

Interested parties should contact info@kanehbosmbiotech.com for more details and a sales presentation or phone 604-782-4191.

On behalf of the Board of Directors of Kaneh Bosm Inc.

"Michael Martinz"

Michael Martinz
President, Director

"Rudy de Jonge"

Rudy de Jonge
CEO, Director

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com.

NOT FOR DISSEMINATION IN THE UNITED STATES

Source: Kaneh Bosm BioTechnolgy